Genentech, Inc.

Sandhya Vinayak Mandlekar

Mark Merchant

Marie Anne Evangelista

Jennifer Lee Schutzman

Stephanie Royer Joo

Ting-Kun Mark Lin

Stuart G Lutzker

Mark Andrew Merchant

Provided herein are combination therapies comprising a KRasinhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

Methods and compositions comprising a KRasinhibitor and a VEGF inhibitor for treating solid tumors

Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).

Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer

Growing community of inventors

Foster City, CA, United States of America

Sandhya Vinayak Mandlekar